Kazia Paxalisib Successfully Combats Triple-Negative Breast Cancer Resistance in Preclinical

Kazia Therapeutics (NASDAQ: KZIA) has unveiled groundbreaking preclinical research published in Molecular Cancer Therapeutics demonstrating that its lead drug paxalisib shows promise in treating triple-negative breast cancer (TNBC). The study, conducted at QIMR Berghofer Medical Research Institute, revealed that paxalisib can effectively reprogram the tumor microenvironment and enhance immune response when combined with immunotherapy. Key findings show that paxalisib's dual targeting of PI3K and mTOR inhibits cancer cell growth, increases T cell infiltration, and demonstrates synergistic antitumor activity when combined with KEYTRUDA, leading to tumor regression in preclinical models. The company has already initiated a Phase 1b clinical trial testing paxalisib in combination with checkpoint inhibitors and chemotherapy for advanced breast cancer, with the first patient dosed.

https://www.stocktitan.net/news/KZIA/kazia-therapeutics-announces-transformative-preclinical-data-j2wprqaz6gz2.html